摘要:
Process for the synthesis of (2S)-indoline-2-carboxylic acid of formula (I): Application in the synthesis of perindopril and its pharmaceutically acceptable salts.
摘要:
Crystalline form IV of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.
摘要:
Stereoselective process for the industrial synthesis of compounds of formula (I): wherein R represents linear or branched (C1-C6)alkyl. Application in the synthesis of perindopril and pharmaceutically acceptable salts thereof.
摘要:
The invention relates to a process for the preparation of the compound of formula I: ##STR1## characterized in that 2,3,4-trimethoxybenzaldehyde is dissolved with piperazine, and then the reaction medium is subjected to the action of hydrogen to give the compound of formula I.
摘要:
Crystalline form III of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.
摘要:
Process for the synthesis of ivabradine of formula (I): addition salts thereof with a pharmaceutically acceptable acid and hydrates thereof. α crystalline form of ivabradine hydrochloride.Medicinal products containing α crystalline form of ivabradine hydrochloride, which are useful as bradycardics.
摘要:
Crystalline form III of the compound of formula (I): characterised by its powder X-ray diffraction diagram.Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.
摘要:
α-crystalline form of the compound of formula (I): characterised by its powder X-ray diffraction diagram.Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme.
摘要:
Process for the synthesis of (2S)-indoline-2-carboxylic acid of formula (I): Application in the synthesis of perindopril and its pharmaceutically acceptable salts.
摘要:
Crystalline form V of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.